Clinical Trial Search

Primary: AUC0-tz of Empagliflozin in Plasma — 5370; 5470 nmol·h/L — p=<0.00001

Primary: Number of Subjects Reporting Local Tolerability Events (Assessed by the Patient and Investigator) — 3; 3; 2; 1 Number of subjects with any symptom

Primary: Area Under the Curve of DOTAREM in Plasma — 1591.1 hour.µmol/L

Primary: Response Rate (RR) — 0; 0; 2; 15 Participants

Primary: Change From Baseline in Participant Hemoglobin A1C Level at Week 24 — -1.28; -1.30 Percent A1C

Primary: Change From Baseline in the Area Under the Curve (AUC) of Breath CH4 Production at Day 7 — 99.2; 57.3; 72.7 hours*ppm

Primary: Point Prevalence of 7-day Tobacco Abstinence Biochemically Validated by Exhaled CO < 10ppm at Visit 3 (12 Weeks After Target Quit Day) — 23; 23 Participants

Primary: Number of Subjects With Moderate to Severe RT-PCR Confirmed Influenza. — 90; 242 Participants

Primary: Overall Success — 62.8; 53.2; 62.7 % of Subjects

Primary: Single Ascending Dose (SAD) Cohort: Change From Baseline in Blood Pressure at Day 1 — 114.2; 110.6; 108.7; 102.8 millimeter of mercury (mmHg)

Primary: Part A: To Establish Highest Tolerated Dose of Lenalidomide, Dose-Limiting Toxicity — 0; 0; 0 Participants

Primary: Primary: Change From Baseline in Hemoglobin A1c (A1C) at Week 24 — -0.62; -0.66 Percent

Primary: Area Under the Concentration -Time Curve of the Analyte in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC 0-tz); Empagliflozin — 6430…

Primary: BIRADS Breast Density — 9; 9; 15; 42 participants

Primary: Change From Study 1 (NCT02495623) Baseline in the Area Under the Curve (AUC) of Breath CH4 Production, Based on a 180-minute Lactulose Breath Test (LBT) at Day 56…